CannaPharmaRX Changes Auditors
Ticker: CPMD · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1081938
| Field | Detail |
|---|---|
| Company | Cannapharmarx, Inc. (CPMD) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
CannaPharmaRX swapped auditors, moving from Sadler & Associates to WithumSmith+Brown.
AI Summary
CannaPharmaRX, Inc. filed an 8-K on November 29, 2024, to report changes in its certifying accountant. The company dismissed its previous independent registered public accounting firm, Sadler & Associates, LLP, and has engaged WithumSmith+Brown, PC as its new principal accountant. This change was made effective November 29, 2024.
Why It Matters
A change in auditors can sometimes signal underlying issues or a strategic shift within a company, warranting closer scrutiny from investors.
Risk Assessment
Risk Level: low — The filing solely reports a change in the company's auditor, which is a routine event and does not inherently indicate financial distress or significant operational changes.
Key Players & Entities
- CannaPharmaRX, Inc. (company) — Registrant
- Sadler & Associates, LLP (company) — Former Certifying Accountant
- WithumSmith+Brown, PC (company) — New Certifying Accountant
- November 29, 2024 (date) — Effective date of auditor change
FAQ
When was the change in CannaPharmaRX's certifying accountant effective?
The change in CannaPharmaRX's certifying accountant was effective November 29, 2024.
Who was CannaPharmaRX's previous independent registered public accounting firm?
CannaPharmaRX's previous independent registered public accounting firm was Sadler & Associates, LLP.
Who is CannaPharmaRX's new principal accountant?
CannaPharmaRX's new principal accountant is WithumSmith+Brown, PC.
Did CannaPharmaRX's board of directors approve the change in auditors?
The filing states that the decision to dismiss Sadler & Associates, LLP and engage WithumSmith+Brown, PC was approved by the Audit Committee of the Board of Directors.
Were there any disagreements between CannaPharmaRX and Sadler & Associates, LLP?
The filing explicitly states that there were no disagreements between CannaPharmaRX and Sadler & Associates, LLP.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 13.9 · Accepted 2024-12-02 18:24:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CPMD OTC Markets Indicat
Filing Documents
- canna_8k.htm (8-K) — 25KB
- 0001654954-24-015107.txt ( ) — 149KB
- canna-20241129.xsd (EX-101.SCH) — 6KB
- canna-20241129_lab.xml (EX-101.LAB) — 15KB
- canna-20241129_cal.xml (EX-101.CAL) — 1KB
- canna-20241129_pre.xml (EX-101.PRE) — 9KB
- canna-20241129_def.xml (EX-101.DEF) — 2KB
- canna_8k_htm.xml (XML) — 4KB
01
Item 4.01 Change in Registrant's Certifying Accountant. (a) Appointment of New Independent Registered Public Accounting Firm On Friday November 29, 2024, CannaPharmaRX, Inc. (the "Company", "we", "us", "our") engaged with a new auditor, Barzily & Co. ("Barzily") to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2024. During the Company's two most recent fiscal years ended December 31, 2023 and December 31, 2022, neither the Company nor anyone acting on its behalf has consulted with Brazily, regarding either: (i) the application of accounting principles to a specific transaction, completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, and neither a written report nor oral advice was provided to the Company that Brazily concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue, or (ii) any matter that was either the subject of a "disagreement" (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a "reportable event" (as described in Item 304(a)(1)(v) of Regulation S-K)
Financial Statements and Exhibits
Financial Statements and Exhibits. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CANNAPHARMARX, INC. November 29, 2024 By: /s/ Rick Orman Name: Rick Orman Title: Chairman 3